Complicated urinary tract infections (cUTIs), whether localized to the lower or upper tract, is associated with an underlying condition that increases the risk of failing therapy. Recently, The US Food and Drug Administration (FDA) approved a combination therapy for adults aged 18 years and older with cUTIs, including pyelonephritis, caused by designated susceptible Enterobacteriaceae. So far, Carbapenem antibiotics have been the preferred drugs for treating severe infections, such as cUTIs.
However, considering the production of Klebsiella pneumoniae carbapenemase enzyme, new drugs that address the resistance mechanism to carbapenems are critical for the management of cUTIs. This new FDA approved combination therapy containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by specific bacteria (Escherichia coli, Klebsiella…
